Developer docs
API playgroundTry for free, no card

Search company profiles

Pulmonx

Full company profile

uuid0003dfb

Namestring
Pulmonx
Legal namestring
Pulmonx Corporation
Websiteurl
pulmonx.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Pulmonx Corporation is a commercial-stage medical technology company that develops and sells minimally invasive devices and diagnostic platforms for the treatment of severe COPD and emphysema. The company's flagship product is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically that allows trapped air to escape damaged lung regions while preventing new air from entering. The Zephyr Valve received FDA approval in 2018 and is sold as an alternative to invasive lung volume reduction surgery. The company is headquartered in Redwood City, California, and was founded in 1995 (with some sources citing 1998); it trades on NASDAQ under ticker LUNG.

Pulmonx sells a procedural ecosystem rather than a single device. The Zephyr Valve is paired with the Chartis Pulmonary Assessment System (a console plus single-use Precision XL catheter that measures collateral ventilation to confirm patient eligibility) and the cloud-based StratX and LungTraX CT analysis platforms, which provide lung assessment reports used by treating physicians for candidate selection. Procedure economics are evidenced by 18% FEV1 improvement, 39-meter six-minute walk distance improvement, and 7.1-point SGRQ quality-of-life gains over controls, supported by four randomized controlled trials (LIBERATE, TRANSFORM, IMPACT, STELVIO).

The company monetizes primarily through hardware sales of Zephyr Valve implants and Chartis capital equipment and catheters to hospitals and treatment centers, with a smaller recurring subscription/analytics revenue stream from StratX and LungTraX. Go-to-market is a direct enterprise field sales motion targeting pulmonologists, interventional bronchoscopists, and hospitals, supported by a trained treatment-center network in 25+ countries, regional offices in Neuchâtel, Munich, and London, and reimbursement support (including NHS access in the UK via NICE). As of FY2025, revenue was $90.5 million with Q3 2025 gross margin of 75%, though the company remains EBITDA-negative.

Short descriptiontext

Pulmonx develops and sells minimally invasive medical devices for severe COPD/emphysema, led by the FDA-approved Zephyr Endobronchial Valve and supported by the Chartis Pulmonary Assessment System and StratX/LungTraX cloud diagnostic platforms, serving pulmonologists and hospitals across 25+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive lung volume reduction, bronchoscopic endobronchial valves, severe emphysema treatment, COPD interventional pulmonology, pulmonary assessment diagnostics
Industry2 codes
PRIMARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Pulmonology Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Zephyr Valve Sales
TypeHardware Sales
Description

Sale of Zephyr Endobronchial Valve implants to hospitals and treatment centers for bronchoscopic lung volume reduction procedures. Revenue recognized per procedure/implant.

defenseworld.net
2Chartis System Sales
TypeHardware Sales
Description

Sale of Chartis Pulmonary Assessment System capital equipment (console) and single-use catheters used during patient assessment for Zephyr Valve eligibility.

pulmonx.com
3Diagnostic Platform Services
TypeSubscription Recurring
Description

Revenue from StratX and LungTraX cloud-based analysis platforms used for patient selection and treatment planning.

stocktitan.net
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations
Pricing details1 tier
1Zephyr Valve treatment available on NHS and privately
ModelOtherBilling cadenceMulti-year contract
Notes

Endobronchial valves including Zephyr Valves are recommended by NICE and available on the NHS in the UK. Private clinic pricing varies by facility. US coverage through Medicare and commercial insurance.

ukpatients.pulmonx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Zephyr Valve
Description

Minimally invasive bronchoscopic treatment for patients with severe COPD/emphysema - the company's primary product

pulmonx.com
+3 more records
Core offering1 text field

Pulmonx develops and commercializes minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. Its core offering is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically to reduce hyperinflation in damaged lung regions without surgery. The offering is supported by the Chartis Pulmonary Assessment System, the StratX and LungTraX cloud-based CT analysis platforms, and AeriSeal lung sealant, sold to hospitals and specialized treatment centers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 18% FEV1 improvement over control
+3 more records
Product overview1 text field

Pulmonx offers a portfolio of minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. The core product is the Zephyr Endobronchial Valve, an implantable bronchial valve that achieves lung volume reduction without surgery. This is supported by the Chartis Pulmonary Assessment System (comprising the Chartis Precision XL Catheter and Chartis Console) for measuring collateral ventilation, and the cloud-based StratX CT analysis platform for patient evaluation. Additional platforms include LungTraX for lung analysis. The Zephyr Valve is FDA-approved and CE-marked (Class IIb, CE 2797), and the products are used in over 25 countries as standard care for severe emphysema.

Product and service6 records
1Zephyr Endobronchial Valve
CategoryInterventional pulmonology implant
Description

Minimally invasive implantable bronchoscopic one-way valve made from nitinol and silicone for the treatment of severe COPD/emphysema hyperinflation. Designed to reduce trapped air in damaged lung regions without surgery. Used by interventional pulmonologists at hospitals and treatment centers.

2Chartis Pulmonary Assessment System
CategoryDiagnostic capital equipment and consumables
Description

Bronchoscopic catheter and console system that measures pressure and flow to calculate resistance to airflow and quantify collateral ventilation in isolated lung compartments. Used by interventional pulmonologists to determine patient eligibility for Zephyr Valve treatment.

3Chartis Precision XL Catheter
CategoryDiagnostic single-use catheter
Description

Single-use catheter component of the Chartis Pulmonary Assessment System, used through the bronchoscope working channel to measure pressure and flow during pulmonary assessment.

4StratX Lung Analysis Platform
CategoryCloud-based diagnostic/analysis platform
Description

Cloud-based CT analysis platform that processes imaging data to generate detailed lung assessment reports for patient evaluation and treatment planning for Zephyr Valve procedures. Identifies candidates based on emphysema heterogeneity and lobar analysis.

5LungTraX Platform
CategoryCloud-based diagnostic platform
Description

Cloud-based platform for lung analysis and patient assessment used in conjunction with other diagnostic tools for emphysema patient evaluation and treatment decisions.

6AeriSeal
CategoryLung volume reduction treatment product
Description

Lung sealant product for lung volume reduction, included in Pulmonx's safety and performance documentation alongside Zephyr Valve and Chartis System as part of the emphysema treatment ecosystem.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Intuitive Surgical's Ion robotic bronchoscopy platform competes in the bronchoscopy procedure ecosystem where Zephyr Valves are implanted. As robotic bronchoscopy becomes standard for lung diagnostics and interventions, Ion could enable competing therapeutic approaches.

TypeBroad incumbent
Description

Stryker is a broad medical device incumbent with surgical and endoscopy instruments used in interventional procedures. While not a direct competitor in bronchoscopic valves, it operates in adjacent procedural medtech categories.

TypeOthers
Description

Karl Storz is a leading manufacturer of rigid and flexible endoscopes used in bronchoscopy procedures. As a supplier of the visualization platforms where Zephyr Valves are implanted, it is an ecosystem participant rather than a direct therapeutic competitor.

TypeBroad incumbent
Description

Boston Scientific acquired PneumRx (lung volume reduction coils) and has historical investment in Pulmonx (Series C investor). It is a broad incumbent in interventional pulmonology and pulmonary devices with overlapping interest in lung volume reduction.

TypeBroad incumbent
Description

Medtronic is a large medical device incumbent with respiratory and pulmonary offerings, including ventilation and interventional products. While not a direct competitor in endobronchial valves, it operates in the broader pulmonary disease management space.

TypeEmerging player
Description

Penumbra has expanded into pulmonary thrombectomy and lung intervention. While historically focused on vascular thrombectomy, its move into pulmonary procedures creates partial overlap with interventional pulmonology workflows where Pulmonx operates.

TypeEmerging player
Description

Broncus Medical develops lung navigation and bronchoscopy tools (including Archimedes Virtual Bronchoscopy), competing in the diagnostic and procedural planning stages that overlap with Pulmonx's StratX and Chartis platforms.

TypeDirect peer
Description

Spiration, an Olympus subsidiary, markets the Spiration Valve System, an endobronchial valve for treating severe emphysema. This is the most direct competitor to Pulmonx's Zephyr Valve in bronchoscopic lung volume reduction.

TypeEmerging player
Description

Johnson & Johnson's Auris Health subsidiary markets the Monarch robotic bronchoscopy platform, directly competing in the bronchoscopic procedure space where Pulmonx's Zephyr Valves are deployed, with potential to enable alternative interventional therapies.

TypeBroad incumbent
Description

Olympus is the parent of Spiration (direct competitor) and a global leader in bronchoscopy equipment and endoscopy. Olympus's installed base of bronchoscopes creates a channel and ecosystem overlap with Pulmonx's interventional pulmonology products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pulmonx

Interventional Pulmonology Medical Devicespulmonx.com

Pulmonx develops and sells minimally invasive medical devices for severe COPD/emphysema, led by the FDA-approved Zephyr Endobronchial Valve and supported by the Chartis Pulmonary Assessment System and StratX/LungTraX cloud diagnostic platforms, serving pulmonologists and hospitals across 25+ countries.

What Pulmonx does

Pulmonx Corporation is a commercial-stage medical technology company that develops and sells minimally invasive devices and diagnostic platforms for the treatment of severe COPD and emphysema. The company's flagship product is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically that allows trapped air to escape damaged lung regions while preventing new air from entering. The Zephyr Valve received FDA approval in 2018 and is sold as an alternative to invasive lung volume reduction surgery. The company is headquartered in Redwood City, California, and was founded in 1995 (with some sources citing 1998); it trades on NASDAQ under ticker LUNG.

Pulmonx sells a procedural ecosystem rather than a single device. The Zephyr Valve is paired with the Chartis Pulmonary Assessment System (a console plus single-use Precision XL catheter that measures collateral ventilation to confirm patient eligibility) and the cloud-based StratX and LungTraX CT analysis platforms, which provide lung assessment reports used by treating physicians for candidate selection. Procedure economics are evidenced by 18% FEV1 improvement, 39-meter six-minute walk distance improvement, and 7.1-point SGRQ quality-of-life gains over controls, supported by four randomized controlled trials (LIBERATE, TRANSFORM, IMPACT, STELVIO).

The company monetizes primarily through hardware sales of Zephyr Valve implants and Chartis capital equipment and catheters to hospitals and treatment centers, with a smaller recurring subscription/analytics revenue stream from StratX and LungTraX. Go-to-market is a direct enterprise field sales motion targeting pulmonologists, interventional bronchoscopists, and hospitals, supported by a trained treatment-center network in 25+ countries, regional offices in Neuchâtel, Munich, and London, and reimbursement support (including NHS access in the UK via NICE). As of FY2025, revenue was $90.5 million with Q3 2025 gross margin of 75%, though the company remains EBITDA-negative.

Pulmonx firmographics

Firmographics
Name
Pulmonx
Legal name
Pulmonx Corporation
Website
https://pulmonx.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
251–500 employees
Short description
Pulmonx develops and sells minimally invasive medical devices for severe COPD/emphysema, led by the FDA-approved Zephyr Endobronchial Valve and supported by the Chartis Pulmonary Assessment System and StratX/LungTraX cloud diagnostic platforms, serving pulmonologists and hospitals across 25+ countries.
Ownership category
akta.pro rank

Pulmonx industry classification

Industry
Product category
Interventional Pulmonology Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management

Keywords

  • Minimally invasive lung volume reduction
  • Bronchoscopic endobronchial valves
  • Severe emphysema treatment
  • COPD interventional pulmonology
  • Pulmonary assessment diagnostics

Where Pulmonx is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Pulmonx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations

Revenue model

  1. Zephyr Valve Sales: Sale of Zephyr Endobronchial Valve implants to hospitals and treatment centers for bronchoscopic lung volume reduction procedures. Revenue recognized per procedure/implant.
  2. Chartis System Sales: Sale of Chartis Pulmonary Assessment System capital equipment (console) and single-use catheters used during patient assessment for Zephyr Valve eligibility.
  3. Diagnostic Platform Services: Revenue from StratX and LungTraX cloud-based analysis platforms used for patient selection and treatment planning.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractZephyr Valve treatment available on NHS and privately

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Pulmonx product offering

Product offering

Core offering

Pulmonx develops and commercializes minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. Its core offering is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically to reduce hyperinflation in damaged lung regions without surgery. The offering is supported by the Chartis Pulmonary Assessment System, the StratX and LungTraX cloud-based CT analysis platforms, and AeriSeal lung sealant, sold to hospitals and specialized treatment centers worldwide.

Product overview

Pulmonx offers a portfolio of minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. The core product is the Zephyr Endobronchial Valve, an implantable bronchial valve that achieves lung volume reduction without surgery. This is supported by the Chartis Pulmonary Assessment System (comprising the Chartis Precision XL Catheter and Chartis Console) for measuring collateral ventilation, and the cloud-based StratX CT analysis platform for patient evaluation. Additional platforms include LungTraX for lung analysis. The Zephyr Valve is FDA-approved and CE-marked (Class IIb, CE 2797), and the products are used in over 25 countries as standard care for severe emphysema.

Differentiator

Problem solved

Functional benefit

Brands

  • Zephyr Valve: Minimally invasive bronchoscopic treatment for patients with severe COPD/emphysema - the company's primary product
  • Chartis System
  • StratX
  • AeriSeal

Products and services

  • Zephyr Endobronchial Valve Minimally invasive implantable bronchoscopic one-way valve made from nitinol and silicone for the treatment of severe COPD/emphysema hyperinflation. Designed to reduce trapped air in damaged lung regions without surgery. Used by interventional pulmonologists at hospitals and treatment centers.
  • Chartis Pulmonary Assessment System Bronchoscopic catheter and console system that measures pressure and flow to calculate resistance to airflow and quantify collateral ventilation in isolated lung compartments. Used by interventional pulmonologists to determine patient eligibility for Zephyr Valve treatment.
  • Chartis Precision XL Catheter Single-use catheter component of the Chartis Pulmonary Assessment System, used through the bronchoscope working channel to measure pressure and flow during pulmonary assessment.
  • StratX Lung Analysis Platform Cloud-based CT analysis platform that processes imaging data to generate detailed lung assessment reports for patient evaluation and treatment planning for Zephyr Valve procedures. Identifies candidates based on emphysema heterogeneity and lobar analysis.
  • LungTraX Platform Cloud-based platform for lung analysis and patient assessment used in conjunction with other diagnostic tools for emphysema patient evaluation and treatment decisions.
  • AeriSeal Lung sealant product for lung volume reduction, included in Pulmonx's safety and performance documentation alongside Zephyr Valve and Chartis System as part of the emphysema treatment ecosystem.

Quantifiable outcome

  • 18% FEV1 improvement over control
  • +3 more outcomes

Companies that use Pulmonx

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Pulmonx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Pulmonx partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

Pulmonx competitors and assessment

Company assessment

Emerging players

  • Intuitive Surgical: Intuitive Surgical's Ion robotic bronchoscopy platform competes in the bronchoscopy procedure ecosystem where Zephyr Valves are implanted. As robotic bronchoscopy becomes standard for lung diagnostics and interventions, Ion could enable competing therapeutic approaches.
  • Penumbra: Penumbra has expanded into pulmonary thrombectomy and lung intervention. While historically focused on vascular thrombectomy, its move into pulmonary procedures creates partial overlap with interventional pulmonology workflows where Pulmonx operates.
  • Broncus Medical: Broncus Medical develops lung navigation and bronchoscopy tools (including Archimedes Virtual Bronchoscopy), competing in the diagnostic and procedural planning stages that overlap with Pulmonx's StratX and Chartis platforms.
  • Johnson & Johnson (Auris Health/Monarch): Johnson & Johnson's Auris Health subsidiary markets the Monarch robotic bronchoscopy platform, directly competing in the bronchoscopic procedure space where Pulmonx's Zephyr Valves are deployed, with potential to enable alternative interventional therapies.

Broad incumbents

  • Stryker: Stryker is a broad medical device incumbent with surgical and endoscopy instruments used in interventional procedures. While not a direct competitor in bronchoscopic valves, it operates in adjacent procedural medtech categories.
  • Boston Scientific: Boston Scientific acquired PneumRx (lung volume reduction coils) and has historical investment in Pulmonx (Series C investor). It is a broad incumbent in interventional pulmonology and pulmonary devices with overlapping interest in lung volume reduction.
  • Medtronic: Medtronic is a large medical device incumbent with respiratory and pulmonary offerings, including ventilation and interventional products. While not a direct competitor in endobronchial valves, it operates in the broader pulmonary disease management space.
  • Olympus Corporation: Olympus is the parent of Spiration (direct competitor) and a global leader in bronchoscopy equipment and endoscopy. Olympus's installed base of bronchoscopes creates a channel and ecosystem overlap with Pulmonx's interventional pulmonology products.

Others

  • Karl Storz: Karl Storz is a leading manufacturer of rigid and flexible endoscopes used in bronchoscopy procedures. As a supplier of the visualization platforms where Zephyr Valves are implanted, it is an ecosystem participant rather than a direct therapeutic competitor.

Direct peers

  • Spiration (Olympus): Spiration, an Olympus subsidiary, markets the Spiration Valve System, an endobronchial valve for treating severe emphysema. This is the most direct competitor to Pulmonx's Zephyr Valve in bronchoscopic lung volume reduction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Pulmonx social profiles

Digital presence

Pulmonx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pulmonx leadership team

Management profile

Number of profiles

Profiles5 records

Pulmonx funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pulmonx M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulmonx

What does Pulmonx do?

Pulmonx develops and commercializes minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. Its core offering is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically to reduce hyperinflation in damaged lung regions without surgery. The offering is supported by the Chartis Pulmonary Assessment System, the StratX and LungTraX cloud-based CT analysis platforms, and AeriSeal lung sealant, sold to hospitals and specialized treatment centers worldwide.

Is Pulmonx a public or private company?

Pulmonx is a public company. It is classified as public and is currently operating.

When was Pulmonx founded?

Pulmonx was founded in 1995. It employs 251 to 500 people.

Where is Pulmonx based?

Pulmonx is headquartered in Redwood City, United States, in the North America region.

How does Pulmonx make money?

Three revenue lines are on record. Zephyr Valve Sales are the primary driver. The others are chartis System Sales and diagnostic Platform Services.

Who are Pulmonx's main competitors?

Emerging players on record are Intuitive Surgical, Penumbra, Broncus Medical and Johnson & Johnson (Auris Health/Monarch). Broad incumbents are Stryker, Boston Scientific, Medtronic and Olympus Corporation. Karl Storz is listed as an others. Spiration (Olympus) is listed as a direct peer.

Does Pulmonx have an API?

No public API is recorded for Pulmonx.

What industry is Pulmonx in?

Pulmonx's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPulmonx to Participate in the Piper Sandler 38th Annual Healthcare ConferencePulmonx Corporation will participate in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 1:30 PM PT. The company will also host in-person investor meetings, with a live and archived webcast available on its website.GlobeNewswirePulmonx to Participate in the Piper Sandler 38th Annual Healthcare ConferencePulmonx Corporation will participate in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on December 2, 2026, at 1:30 PM PT. The company will also host in-person investor meetings, with a live and archived webcast available on its website.FinanzNachrichten.dePulmonx Corporation: Pulmonx gibt Veröffentlichung der CONVERT-Versuchsergebnisse für AeriSeal System bekanntPulmonx published CONVERT study results showing AeriSeal converted 75.8% of patients from positive to negative collateral ventilation, enabling Zephyr valve treatment. 88.9% of treated patients achieved significant lung volume reduction at 45 days, lasting 12 months. The company is now recruiting for the regulatory CONVERT II study.The Motley FoolPulmonx: 3 Key Takeaways for Long-Term InvestorsPulmonx reported Q3 2026 revenue of $22.8 million, up 7% year-over-year, with adjusted EBITDA loss cut nearly 60%. The company is expanding its addressable market through AeriSeal trials and expects top-line growth to continue in 2026.American Banking and Market NewsComparing Pulmonx (NASDAQ:LUNG) & Brainsway (NASDAQ:BWAY)A comparison of Brainsway and Pulmonx evaluates profitability, valuation, and analyst ratings. Pulmonx shows higher revenue ($90.5M vs $52.2M) but negative earnings, while Brainsway has positive earnings. Analysts favor Pulmonx with a 199.48% upside versus Brainsway's 63.23%.American Banking and Market NewsPulmonx (NASDAQ:LUNG) Stock Gets Price Target Boost from Stifel NicolausStifel Nicolaus raised its price target on Pulmonx from $2.50 to $4.00, keeping a buy rating. The stock opened at $3.16, and insiders sold 78,340 shares in the last 90 days. Analysts have a consensus 'Moderate Buy' rating with a target of $7.67.TradingViewStifel maintains Buy rating on Pulmonx, $4 price targetStifel maintained a Buy rating on Pulmonx with a $4 price target, implying 102% upside from the Oct 27 close. Pulmonx reported Q3 U.S. sales up 6.8% year-over-year and cut operating expenses by 18% while achieving a 76.2% gross margin.TradingViewPulmonx Corporation Stock 12‑Month Price Target Raised to $3.7, Implies 87% UpsideAnalysts' average price target for Pulmonx Corporation rose to $3.7 from $3.4, implying about 87% upside from the Oct. 27 closing price. The consensus remains a Buy across five analysts, with three Buys and two Holds.Seeking AlphaPulmonx reiterates $90M-$92M 2026 revenue outlook while guiding to $108M-$109M operating expenses (NASDAQ:LUNG)Pulmonx reported Q3 2026 revenue of $22.8 million, marking a return to year-over-year growth. The company reiterated its full-year revenue outlook of $90 million to $92 million and guided operating expenses to $108 million to $109 million.Seeking AlphaPulmonx Corporation (LUNG) Q3 2026 Earnings Call TranscriptPulmonx Corporation held its Q3 2026 earnings call on October 27, 2026, with CEO Glen French and CFO Derrick Sung. The call included forward-looking statements about future financial performance, clinical trials, and commercial expansion, but no specific financial results were disclosed in the transcript.